Palvella Therapeutics (NASDAQ:PVLA) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Palvella Therapeutics (NASDAQ:PVLA) from an outperform rating to a strong-buy rating in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm currently has $143.00 target price on the stock, up from their previous target price of $92.00.

Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald upped their price objective on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. HC Wainwright boosted their price target on shares of Palvella Therapeutics from $95.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Stifel Nicolaus increased their price objective on shares of Palvella Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. TD Cowen raised their price objective on shares of Palvella Therapeutics from $65.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Chardan Capital restated a “buy” rating and issued a $110.00 target price on shares of Palvella Therapeutics in a research report on Thursday, November 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Palvella Therapeutics has an average rating of “Buy” and an average price target of $111.92.

Palvella Therapeutics Trading Up 2.8%

PVLA opened at $94.09 on Wednesday. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $101.94. The stock has a market cap of $1.11 billion, a PE ratio of -35.78 and a beta of -0.05. The business’s 50 day moving average is $72.01 and its 200-day moving average is $46.93.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). As a group, analysts forecast that Palvella Therapeutics will post -3.69 EPS for the current year.

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total transaction of $370,961.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PVLA. Summit Partners Public Asset Management LLC acquired a new position in shares of Palvella Therapeutics in the 3rd quarter worth $2,188,000. Mariner LLC acquired a new position in shares of Palvella Therapeutics in the 3rd quarter valued at $1,299,000. Fred Alger Management LLC boosted its position in shares of Palvella Therapeutics by 1,279.1% in the 3rd quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock valued at $11,707,000 after purchasing an additional 173,209 shares during the period. First Light Asset Management LLC acquired a new stake in Palvella Therapeutics during the 3rd quarter worth about $33,949,000. Finally, Bank of America Corp DE raised its holdings in Palvella Therapeutics by 12.3% during the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after buying an additional 515 shares during the period. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.